Market capitalization | €407.07m |
Enterprise Value | €563.85m |
P/E (TTM) P/E ratio | 23.91 |
EV/FCF (TTM) EV/FCF | 4.64 |
EV/Sales (TTM) EV/Sales | 0.31 |
P/S ratio (TTM) P/S ratio | 0.22 |
P/B ratio (TTM) P/B ratio | 0.81 |
Revenue growth (TTM) Revenue growth | 9.95% |
Revenue (TTM) Revenue | €1.84b |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
6 Analysts have issued a Medios forecast:
6 Analysts have issued a Medios forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,838 1,838 |
10%
10%
|
|
Gross Profit | 53 53 |
4%
4%
|
|
EBITDA | 51 51 |
1%
1%
|
EBIT (Operating Income) EBIT | 29 29 |
1%
1%
|
Net Profit | 16 16 |
9%
9%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medios AG is a holding company, which engages in the provision of pharmaceutical drugs. It operates through the following segments: Provision of Medicinal Products, Patient-specific Therapies, and Services. The Provision of Medicinal Products segment focuses on specialty pharmaceuticals means it trades almost exclusively in expensive medicinal products for chronic and/or rare diseases. The Patient-specific Therapies segment include infusions constituted and produced on the basis of individual symptoms and individual parameters such as body weight and body surface. The Services segment consists of all other Group activities, including Medios Group holding activities. The company was founded in 1980 and is headquartered in Berlin, Germany.
Head office | Germany |
CEO | Matthias Gärtner |
Employees | 515 |
Founded | 1980 |
Website | www.medios.ag |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.